Roles of cancer-associated fibroblasts (CAFs) in anti- PD-1/PD-L1 immunotherapy for solid cancers

Molecular Cancer

Review

Shuochen Gao¹  Yang Liu²  Yan Zhang³  Xueyan Gao³  Yudi Feng³  Liping Pei⁴  Chengzeng Wang⁴  Lin Liu⁴  Zhenqiang Sun⁵ 

[1] Department of Neurology, The First Affiliated Hospital of Zhengzhou University, 450052, Zhengzhou, Henan, China;Department of Radiotherapy, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, 450008, Zhengzhou, China;Department of Ultrasound, The First Affiliated Hospital of Zhengzhou University, 450052, Zhengzhou, Henan, China;Department of Ultrasound, The First Affiliated Hospital of Zhengzhou University, 450052, Zhengzhou, Henan, China;Henan Institute of Interconnected Intelligent Health Management, The First Affiliated Hospital of Zhengzhou University, 450052, Zhengzhou, Henan, China;Henan Institute of Interconnected Intelligent Health Management, The First Affiliated Hospital of Zhengzhou University, 450052, Zhengzhou, Henan, China;Department of Colorectal Surgery, The First Affiliated Hospital of Zhengzhou University, 450052, Zhengzhou, Henan, China;

关键词: Cancer-associated fibroblasts;    PD-1/PD-L1 inhibitors;    Immunotherapy;   

DOI  :  10.1186/s12943-023-01731-z

 received in 2022-11-13, accepted in 2023-01-24,  发布年份 2023

来源: Springer

【 摘 要 】

In recent years, breakthroughs have been made in tumor immunotherapy. However, tumor immunotherapy, particularly anti-PD-1/PD-L1 immune checkpoint inhibitors, is effective in only a small percentage of patients in solid cancer. How to improve the efficiency of cancer immunotherapy is an urgent problem to be solved. As we all know, the state of the tumor microenvironment (TME) is an essential factor affecting the effectiveness of tumor immunotherapy, and the cancer-associated fibroblasts (CAFs) in TME have attracted much attention in recent years. As one of the main components of TME, CAFs interact with cancer cells and immune cells by secreting cytokines and vesicles, participating in ECM remodeling, and finally affecting the immune response process. With the in-depth study of CAFs heterogeneity, new strategies are provided for finding targets of combination immunotherapy and predicting immune efficacy. In this review, we focus on the role of CAFs in the solid cancer immune microenvironment, and then further elaborate on the potential mechanisms and pathways of CAFs influencing anti-PD-1/PD-L1 immunotherapy. In addition, we summarize the potential clinical application value of CAFs-related targets and markers in solid cancers.

【 授权许可】

CC BY   
© The Author(s) 2023

【 图 表 】

Fig. 6

Fig. 2